Author

M. Kankainen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Hemmes· 1 shared A. Knuuttila· 1 shared A. Näätänen· 1 shared A.-L. Levonen· 1 shared B. Ghimire· 1 shared C. S. Mitsiades· 1 shared D. A. Lee· 1 shared D. Barbie· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Hemmes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Single-cell functional genomics of natural killer cell evasion in blood cancers

O. Dufva, S. Gandolfi, J. Huuhtanen, O. Dashevsky, K. Saeed, J. Klievink, P. Nygren, J. Bouhlal, J. Lahtela, A. Näätänen, B. Ghimire, T. Hannunen, P. Ellonen, H. Duan, J. Theodoropoulos, , S. Mustjoki

The paper uses single-cell and genome-scale functional genomics to study how blood cancer cells evade NK cells, identifying key genes and pathways involved in resistance and sensitivity.

bioRxiv · Aug 22, 2022 · PreprintImmunology

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer

K. Wennerberg, E. W. Verschuren, S. Talwelkar, M. I. Mäyränpää, J. Schüler, N. Linnavirta, A. Hemmes, S. Adinolfi, M. Kankainen, W. Sommergruber, A.-L. Levonen, J. Räsänen, A. Knuuttila

The paper identifies PI3Kβ as a mediator of resistance to ALK inhibitors in ALK-rearranged lung cancer and shows that combining ALK and PI3Kβ inhibitors overcomes resistance.

bioRxiv · Mar 18, 2021 · PreprintCancer Biology

Association of tamoxifen resistance and lipid reprogramming in breast cancer.

S. Hultsch, M. Kankainen, L. Paavolainen, R.-M. Kovanen, E. Ikonen, S. Kangaspeska, V. Pietiaeinen, O. Kallioniemi

This study identifies lipid reprogramming and lysosomal membrane permeabilization (LMP) prevention as key mechanisms of tamoxifen resistance in breast cancer, suggesting new therapeutic targets.

bioRxiv · Jun 25, 2018Cancer Biology